Figures & data
Table I. Patient characteristics (second-line therapy – capecitabine and oxaliplatin).
Table II. Treatment-related toxicities* (No of cycles = 99) - rates in brackets.
Table III. Second-line chemotherapy regimens in CUP patients.
Hainsworth JD, Burris HA, III, Calvert SW, Willcutt NT, Scullin DC, Jr., Bramham J, . Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001;19:335–9. Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001;21:1455–7. Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, . Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003;23:2801–4. Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, . Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005;104:1992–7.